Supernus Pharmaceuticals reported $401.44M in Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Aerie Pharmaceuticals AERI:US USD 312.59M 458K
Ani Pharmaceuticals ANIP:US USD 286.73M 213K
Aurora Cannabis Inc ACB:CN CAD 325.57M 56.08M
Bristol Myers Squibb BMY:US USD 39.1B 2.96B
Canopy Growth Corp WEED:CN CAD 1.48B 111.05M
Eisai 4523:JP JPY 94.91B 8M
Eli Lilly And LLY:US USD 15.89B 925.4M
Endo International Ordinary Shares ENDP:US USD 1.42M 8.09B
Horizon Pharma HZNP:US USD 2.57B 1.85M
Lannett LCI:US USD 619.34M 4.39M
Marinus Pharmaceuticals MRNS:US USD 70.78M 430K
Pacira Pharmaceuticals PCRX:US USD 747.87M 7.78M
Perrigo Ordinary Shares PRGO:US USD 4.11B 5.9M
Revance Therapeutics RVNC:US USD 388.28M 7.82M
Supernus Pharmaceuticals SUPN:US USD 401.44M 529K
Teva Pharmaceutical Industries TEVA:US USD 21.27B 816M
United Therapeutics UTHR:US USD 800M 0
Xeris Pharmaceuticals Inc XERS:US USD 138.51M 439K